Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in Advanced NSCLC Patients With ECOG PS 2
NCT02879617Phase 2Completed
- Sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
- Start
- Apr 2017
- Primary completion
- Jun 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Academic Thoracic Oncology Medical Investigators Consortium. Primary endpoints: Overall Survival at 30 months, Overall Survival at 12 Months and 2 more. Started Apr 2017; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02879617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02879617.